Irsenontrine_product_DataBase

Bioactivity	Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases[1][2][3].
Target	PDE9
Invitro	Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE 9) inhibitor[3].
In Vivo	Irsenontrine (0.3, 3.3 mg/kg; p.o.) exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats[1].Irsenontrine (1 mg/kg; p.o.) and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone[1].
Name	Irsenontrine
CAS	1429509-82-9
Formula	C22H22N4O3
Molar Mass	390.44
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Reference	[1]. Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1 [2]. Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319. [3]. Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases

PeptideDB